STAT+: Bluebird submits sickle cell gene therapy to FDA for approval
Gene therapy developer Bluebio Bio said it has submitted a long-awaited application asking the FDA to approve its drug for sickle cell disease.
Gene therapy developer Bluebird Bio said Monday that it has submitted a long-awaited application asking the Food and Drug Administration to approve its drug for sickle cell disease, setting up competition with Vertex Pharmaceuticals and CRISPR Therapeutics.
Bluebird’s treatment, called lovo-cel, is a gene therapy that uses an engineered virus to insert a modified gene into the DNA of a patient’s stem cells. The gene produces normally functioning hemoglobin, which patients with sickle cell disease lack. Instead, their oxygen-carrying hemoglobin is rigid, sticky, and misshapen, and can block blood vessels, inhibiting the flow of oxygen through the body.
What's Your Reaction?
